Observational study / 2018
Elevated serum vitamin B12 levels were associated with significantly shorter survival times in patients with metastatic cancer.
A retrospective chart review of 523 metastatic cancer patients examined serum vitamin B12 as a prognostic factor. Median survival time was 1.8 months in the high B12 group (>911 pg/mL) compared to 5.1 months in the normal B12 group (211-911 pg/mL) (p < 0.001). Among patients without liver lesions, median survival was 2.1 months in the high group versus 6.1 months in the normal group (p < 0.001). Multivariate analysis identified serum vitamin B12 as an independent prognostic factor for overall survival (HR: 1.62; 95% CI: 1.34-1.96, p < 0.001).
Shows an association, not proof of cause and effect.
- Study type
- Retrospective cohort study
- Who was studied
- 523 metastatic cancer patients
- What was measured
- Survival time / overall survival
THE PAPER
Elevated Serum Vitamin B12 Levels as a Prognostic Factor for Survival Time in Metastatic Cancer Patients: A Retrospective Study.
Oh HK, Lee JY, Eo WK, Yoon SW, Han SN. Nutr Cancer, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.